JPRN-UMIN000008802已完成2 期
Safety trial of eriburin treatment to patient who has peripheral neuropathy - H(Hiroshima)-STEP
Dept of surgical oncology, Hiroshima university hospital0 个研究点目标入组 48 人开始时间: 2012年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Forbidden case to use eribulin 2)Serious bone marrow suppression 3)Allergy to component of eribulin 4)Pregnant or like be pregnant 5)Serious liver or renal disorder 6)Inadequate interval from prior therapy 7)Symptomatic brain metastasis 8)Patient with CNS disease, DM, RA, or bone metastasis (possible involvement peripheral neropathy) 9)Peripheral neuropathy caused from surgery 10)With doctors decision for exclusion
研究者
相似试验
已完成
不适用
Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanesBreast cancerJPRN-UMIN000007121Kyushu Breast Cancer Study Group50
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
已完成
2 期
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistanceBreast CancerJPRN-UMIN000006965Saitama Breast Cancer Clinical Study Group (SBCCSG)52
已完成
不适用
Randomised trial comparing the efficacy of epirubicin, cisplatin and 5-fluorouracil (FEC) to 5-fluorouracil, methotrexate and adriamycin (FAMTX) in patients with gastric and oesophageal cancerOesophagus, stomach cancerOesophagus, stomachCancerISRCTN37398231Cancer Research UK (CRUK) (UK)
已完成
不适用
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35